

**BG-12 MS
Clinical Development Team**

Subject: Minutes from BG-12 MS CDT meeting on 17 May 2006
Date: 18 May 2006

Attendees: Cara Lansden, Gilmore O'Neill, Minhua Yang, Ratna Lingamaneni, [REDACTED], Tammy Samelli, [REDACTED]

1	Phase 3 protocol design feedback from IMSEF	<ul style="list-style-type: none">Attached below is the table containing IMSEF comments. (International MS Expert Forum – a meeting of BiIB consultants)
---	---------------------------------------------	------------------------------------------------------------------------------------------------------------------------------------------------------------------------



2	Phase 3 Protocol update	<ul style="list-style-type: none">The Phase 3 protocol concepts were approved by C. Bozic on 16 May, and SMTs are being formed to draft the protocol.
3	Feasibility update	<ul style="list-style-type: none">734 questionnaires were sent out.85 questionnaires were completed (12%).Out of 85 sites, 60 sites said they could enroll in a 2-year placebo-controlled study where a patient had to remain on placebo for the full 2-years, regardless of relapse.Of the 25 investigators who would not keep patients on placebo for 2 years, 17 of them were from the US.
4	AOB	<ul style="list-style-type: none">N/A







